Overcoming mutation-based resistance to antiandrogens with rational drug design

Overcoming mutation-based resistance to antiandrogens with rational drug design

The second-generation antiandrogen enzalutamide was recently approved for patients with castration-resistant prostate cancer. Despite its success, the duration of response is often limited. For previous antiandrogens, one mechanism of resistance is mutation of the androgen receptor (AR). To prospect...

Full description

Bibliographic Details
Main Authors: Minna D Balbas, Michael J Evans, David J Hosfield, John Wongvipat, Vivek K Arora, Philip A Watson, Yu Chen, Geoffrey L Greene, Yang Shen, Charles L Sawyers
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2013-04-01
Series:eLife
Subjects:
prostate cancer
androgen receptor
drug resistance
Online Access:https://elifesciences.org/articles/00499

Internet

https://elifesciences.org/articles/00499

Similar Items